Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes (Q54806474)

Hereditary auto-inflammatory disorders and biologics

21 January 2018

1 reference

Inflammasome components NALP 1 and 3 show distinct but separate expression profiles in human tissues suggesting a site-specific role in the inflammatory response

21 January 2018

1 reference

The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta

21 January 2018

1 reference

Gout-associated uric acid crystals activate the NALP3 inflammasome

21 January 2018

1 reference

The Nalp3 inflammasome is essential for the development of silicosis

21 January 2018

1 reference

Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants

21 January 2018

1 reference

The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response

21 January 2018

1 reference

Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration

21 January 2018

1 reference

In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes

21 January 2018

1 reference

Interleukin-1-receptor antagonist in the Muckle-Wells syndrome.

21 January 2018

1 reference

Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition

21 January 2018

1 reference

Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies

21 January 2018

1 reference

Primer: inflammasomes and interleukin 1beta in inflammatory disorders

21 January 2018

1 reference

Response to anakinra in a de novo case of neonatal-onset multisystem inflammatory disease

21 January 2018

1 reference

Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist

21 January 2018

1 reference

Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations

21 January 2018

1 reference

New CIAS1 mutation and anakinra efficacy in overlapping of Muckle-Wells and familial cold autoinflammatory syndromes

21 January 2018

1 reference

Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra.

21 January 2018

1 reference

Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism

21 January 2018

1 reference

Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome

21 January 2018

1 reference

Effect of anakinra on arthropathy in CINCA/NOMID syndrome

21 January 2018

1 reference

A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome

21 January 2018

1 reference

Prevention and reversal of nephritis in MRL/lpr mice with a single injection of C-reactive protein.

21 January 2018

1 reference

The NLRP3 inflammasome, a target for therapy in diverse disease states

21 January 2018

1 reference

High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice

21 January 2018

1 reference

The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis

21 January 2018

1 reference

Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations

21 January 2018

1 reference

Use of canakinumab in the cryopyrin-associated periodic syndrome

21 January 2018

1 reference

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA).

21 January 2018

1 reference

12.4 ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS).

21 January 2018

1 reference

Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade

21 January 2018

1 reference

Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade

21 January 2018

1 reference